In management of Covid-19 many vaccines had developed to date and still 105 vaccines are in clinical trials. According to statistics and research, 6.54 billion doses of covid-19 vaccines have been given to people worldwide till October 2021. After the approval of vaccines by the government of Pakistan, a hyped has been created by citizens of Pakistan about side effects of vaccines. So, we have performed a survey to evaluate the side effects of covid-19 vaccines in population of Karachi this survey is performed to scrutinize the effects people experienced after getting vaccinated. We have collected information from august to September 2021 through online portal The data we have gathered is limited because only 500 people have filled the form. we also tried to evaluate factors involved in causing any side effect by comparing patients factors Some people get experienced the undesirable effects, majority of participants i.e 87.8% had not effected with covid-19 before getting vaccinated, some people felt shortness of breath Moreover, some participants had noticed some other effects included cough, drowsiness and muscle pain. We have regulated the survey randomly and concluded that most of average populace favoured Sinovac with minimal side effects.

<div>Severe Acute Respiratory Syndrome (SARS-CoV2) infected about 93 million people and killed over two million worldwide. The disease transmits very quickly, therefore; due to its severity and widespread the World Health Organization has declared this menace as ‘Global Pandemic’. An urgent need was felt to manage this disease through aggressive and efficient research process all over the globe. That’s why drug re-purposing of 212 chemical entities (CEs) against SARS-COV2 was found to be one of the efficient ways in finding new indications of already discovered drugs amisdst of the discovery of a new drug. Results of this study revealed that out of 212 CEs, only Etodolac forms a hydrogen (H)-bond with a relatively low energy and active central fragment, demonstrating more significant interaction with SARS-CoV2 viral proteins. Other CEs exhibit good pharmacokinetics properties with the least acute toxicity through ADMET analysis. We also discovered other therapeutic applications of these CEs through Molinspiration. Etodolac, a non-steroidal anti-inflammatory drug forms H-bonding with 5.6 kcal/mol binding energy with active residues of this receptor. This drug created H-bonding with PHE326 and PRO328, with pyridine group, and was found more suitable to control SARS-CoV2.</div>